Clinical Trial Update: Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial from Wake Forest University Health Sciences is evaluating neoadjuvant chemotherapy for borderline resectable and locally advanced pancr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Adenocarcinoma
• Pancreatic Adenocarcinoma

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: RECRUITING